Loading patent…
AssigneeNational Center of Neurology and Psychiatry
InventorsTakashi Yamaura, Shinji Oki, Benjamin Joseph Edward Raveney, Wakiro Sato, Tomoko Okamoto
Estimating the term…
The present invention provides a therapeutic agent for progressive disease caused by an increase in Eomes-positive CD4-positive T cells, comprising a compound represented by formula (I) or a salt thereof as an active ingredient. In the formula, R1 is an aldopyranose residue, R2 is a hydrogen atom or a hydroxy group, R3 is —CH2—, —CH(OH)—CH2—, or —CH═CH—, R4 is a hydrogen atom or CH3, x is 0 to 35, and y and z each are an integer satisfying y+z=0 to 3.
A composition for treating progressive disease caused by an increase in Eomes-positive CD4-positive T cells, the composition comprising a compound represented by formula (I) or a salt thereof as an active ingredient:
A method for treating a progressive disease caused by an increase in Eomes-positive CD4-positive T cells, the method comprising administering a composition comprising the compound represented by formula (I) or a salt thereof as an active ingredient:
A method for treating a progressive disease caused by an increase in Eomes-positive CD4-positive T cells, the method comprising administering a composition comprising the compound represented by (2S,3S,4R)-1-O-(α-D-galactosyl)-2-(N-tetracosanoylamino)-1,3,4-nonanetriol or a salt thereof.
Dependencies are inferred from the claim text.